HROW forecasts a Q2 2026 EPS loss of $0.24 and revenue of $70.35M, reflecting a 10.4% year-over-year increase.
Harrow Health will report Q2 2026 earnings on August 10 after market close. Analysts expect a loss of $0.24 per share, widening from the prior year, alongside revenue of $70.35M, up 10.4% year-over-year.
The company has faced volatility in earnings over the past two years, with revenue growth outpacing bottom-line performance. Consensus estimates reflect a challenging quarter for profitability despite top-line expansion.
No immediate market reaction details were provided ahead of the release.